1. Hungary Stocks

  2. •

    Healthcare

  3. •

    Medical - Pharmaceuticals
Gedeon Richter PLC

Gedeon Richter PLC

GEDSF
Gedeon Richter PLCUS flagOther OTC
24.85
USD
- -
- -
4.54BMarket Cap
Gedeon Richter PLC
GEDSF
(Other OTC)

Recent

price

24.85

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
1,478.9
1,655.12
1,763.89
1,891.95
1,911.85
1,971.11
2,096.82
2,386.18
2,391.04
2,729.91
3,047.66
3,390.15
4,308.17
4,357.65
4,685.63
5,080.24
4,404.54
Revenue per Share
347.23
264.94
265.85
229.94
134.86
290.7
356.21
47.71
189.72
253.4
562.9
750.65
907.39
859.72
1,307.23
1,270.58
1,243.76
Basic EPS, GAAP
-75.37
272.5
173.62
216.87
102.52
333.24
220.43
235.3
226.97
215.73
359.64
-18.24
614.05
157.12
1,178.32
1,148.43
674.05
Free Cash Flow per Basic Share
76.86
85.98
65.9
65.93
57.31
33.7
72.98
106.09
68.02
101.34
72.59
226.55
226.19
394.35
432.09
509
428.46
Dividend per Share
2,238.89
2,420.04
2,635.48
2,788.23
2,874.97
3,130.12
3,407.6
3,336
3,460.23
3,614.46
4,140.68
4,668.47
5,358.73
5,866.94
6,762.09
7,534.27
6,175.06
Book Value per Share
1,410.22
1,598.65
1,831.17
1,906.54
1,873.13
2,173.26
2,262.95
2,495.34
2,676.72
3,052.16
3,448.05
3,586.42
4,518.96
4,764.3
5,209.3
5,825.86
4,547.48
Tangible Book Value per Share
186
186
185
186
185
185
186
186
186
186
186
186
186
185
183
183
184
Basic Weighted Avg Shares
275,312
307,868
326,702
351,886
353,709
365,220
389,690
444,356
445,484
507,794
566,776
630,595
802,755
805,158
857,545
928,962
811,415
Sales/Revenue/Turnover
22.76
19.79
14.91
13.2
10.67
18.26
16.07
16.86
16.53
16.47
23.12
23
25.29
30.6
31.54
35.19
33.18
Operating Margin (%)
21,135
24,459
26,883
28,301
29,363
31,248
32,895
34,747
34,907
39,320
39,846
44,922
48,569
50,808
52,760
60,463
49,650
Depreciation Expense
64,640
49,281
49,240
42,766
24,950
53,863
66,200
8,885
35,348
47,135
104,683
139,626
169,076
158,850
239,244
232,335
229,129
Net Income, GAAP
4.63
0.44
1.69
2.76
2.95
10.04
1.76
27.56
17.66
4.76
7.91
3.68
- -
6.35
14.78
18.44
9.75
Effective Tax Rate (%)
23.48
16.01
15.07
12.15
7.05
14.75
16.99
2
7.93
9.28
18.47
22.14
21.06
19.73
27.9
25.01
28.24
Profit Margin (%)
181,735
202,675
240,422
226,906
197,702
236,296
220,734
223,345
265,920
300,018
341,580
289,409
396,263
420,405
459,634
600,978
378,582
Working Capital
41,694
62,226
73,163
54,781
44,155
37,188
28,874
3
2
10,296
10,754
18,649
15,986
18,457
19,589
18,102
15,213
LT Debt
442,115
489,856
520,074
551,196
560,212
618,389
681,873
664,019
685,745
724,873
813,939
923,022
1,073,847
1,142,581
1,303,862
1,400,889
1,173,215
Total Equity
13.75
11.74
8.42
7.52
5.98
9.43
8.92
7.84
8.97
11.16
15.38
15.74
- -
20.09
18.24
18.93
21.02
Return on Invested Capital (%)
18.46
10.3
9.47
7.79
4.46
9
10.18
1.3
5.41
6.91
13.99
16.38
- -
15.93
20.86
18.02
16.28
Return on Capital (%)
16.51
11.37
10.5
8.5
4.75
9.69
10.91
1.42
5.58
7.16
14.52
17.04
18.11
15.26
20.61
17.77
21.63
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'23
Mar'24
Jun'24
ST Debt
6,393
- -
40,531
LT Borrowings
4,640
- -
357
LT Finance Leases
13,817
- -
14,856
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
183
- -
183
Market Capitalization
1,469,895
1,531,122
1,699,938

Working Capital

FRC

•

in mil. unless spec.
Dec'23
Mar'24
Jun'24
Total Current Assets
534,913
- -
545,884
Cash, Cash Equivalents & STI
88,186
- -
57,854
Accounts Receivable, Net
204,968
- -
234,136
Inventories
177,767
- -
205,752
Total Current Liabilities
114,508
- -
167,302
Payables & Accruals
- -
- -
- -
ST Debt
6,393
- -
40,531
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
8.66%
11.54%
7.44%
Free Cash Flow
-298.03%
-602.33%
-2.62%
Net Income, GAAP
48.57%
19.23%
-2.89%
Sales/Revenue/Turnover
10.03%
10.74%
8.33%
Total Cash Common Dividend
45.86%
62.25%
17.7%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
209,653
203,783
188,544
203,178
805,158
2024
203,432
216,261
- -
- -
857,545
2025
224,024
241,485
- -
- -
928,962

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
210
- -
294
- -
859.72
2024
373
- -
- -
- -
1,307.23
2025
373
- -
- -
- -
1,270.58

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
0.46
- -
394.35
2024
0.02
- -
- -
- -
432.09
2025
0.01
- -
- -
- -
509
Similar Companies
Mercury Laboratories Limited (MERCURYLAB.BO)
Shukra Pharmaceuticals Limited (SHUKRAPHAR.BO)
Irwin Naturals Inc. (IWINF)
Cellular Goods PLC (CBX.L)
POZEN Inc. (POZN)
Islet Holdings, Inc. (ISHI)
Business
Gedeon Richter Plc. (GEDSF), headquartered in Budapest, Hungary, and founded in 1901, develops, manufactures and markets pharmaceuticals with a focus on women's healthcare, central nervous system disorders, biotechnology and general medicines; its core products include women's health solutions for contraceptives such as Drovelis and Evra, endometriosis therapies like Ryeqo, fertility and menopause treatments including Lenzetto, alongside CNS treatments comprising Vraylar royalties and Reagila, biosimilars such as teriparatide, contract development and manufacturing organization services, and generic pharmaceuticals including novel oral anticoagulants. The company operates through pharmaceuticals, wholesale and retail distribution, and other segments, serving markets across the European Union, CIS countries, Asia-Pacific including China, the United States, Latin America and Eastern Europe with manufacturing sites in Budapest, Dorog and Debrecen, joint ventures in India with Themis Medicare and in Germany with Helm AG. Recent developments include a strategic investment and collaboration with Granata Bio in 2025 to expand U.S. fertility market presence through equity stake acquisition and board representation; a new R&D partnership with AbbVie on neuropsychiatry program RGH-932 advancing to phase 2 trials; establishment of a women's healthcare original research hub in Belgium; biosimilar milestones for three candidates; acquisition of RHT enhancing teriparatide capabilities announced in 2024; and an active M&A pipeline including a June 2024 acquisition tied to novel kinase inhibitors, supporting robust revenue growth to HUF 845bn in 2024 and revised 2025 guidance near EUR 2.3bn ex-FX.

Company News

APIChat

  • seekingalpha.com

    Gedeon Richter PLC (GEDSF) Q1 2026 Earnings Call Transcript